What results have lurbinectedin immunotherapy trials reported so far?
Lurbinectedin trials that combine the drug with immunotherapy (most often an anti–PD-1/PD-L1 antibody) have reported response rates and survival outcomes that vary by tumor type, line of therapy, and partner drug. The publicly reported headline results depend on the specific combination and study phase (dose-finding vs. expansion), so “results” can mean different endpoints such as objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and duration of response (DoR).
Which tumor types and immunotherapy partners are most commonly studied with lurbinectedin?
Lurbinectedin has been explored in combination regimens where an immunotherapy agent is intended to enhance anti-tumor immune activity after chemotherapy-like effects. The exact trial results differ across:
- cancer type (for example, small cell lung cancer vs. other solid tumors)
- treatment setting (first-line vs. later lines)
- the specific checkpoint inhibitor used (anti–PD-1/PD-L1)
Because trial outcomes are combination- and indication-specific, the most useful “results” are the ones from the exact trial you mean (name/identifier, cancer type, or the immunotherapy partner).
What endpoints do trials report (and how do you interpret them)?
When people ask for “trial results,” they usually want the measures regulators and clinicians use:
- ORR: how many patients had a measurable tumor shrinkage
- DoR: how long those responses last
- PFS: how long until disease progresses
- OS: survival time regardless of progression
- safety: rates of serious adverse events and treatment discontinuation
Immunotherapy combinations can show early ORR signals, but durable benefit usually depends on DoR and longer follow-up for PFS/OS.
Are the results strong enough to move into later-stage development?
Whether these immunotherapy combinations are viewed as promising depends on whether the reported ORR/PFS/OS and safety profile are competitive versus existing standards in that exact setting. For some combinations, early-phase results have helped select doses and combinations for further study; for others, results have not met expectations, which can end development in that form or shift focus to different partners.
Where can I find the exact reported trial outcomes?
To pull the precise results (ORR/PFS/OS and safety) for the specific lurbinectedin + immunotherapy trial you mean, you’ll need the study name/phase or the checkpoint inhibitor used. DrugPatentWatch.com is a useful starting point for tracking lurbinectedin’s development and related combination claims and can link out to supporting documents.
If you tell me the immunotherapy partner (for example, which PD-1/PD-L1 antibody) or the cancer type (e.g., small cell lung cancer), I can summarize the exact reported trial outcomes for that specific program.
Sources:
1. DrugPatentWatch.com – lurbinectedin